Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biovectra, Revolution Biomanufacturing Partner to Streamline mRNA Development & Scale-Up | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Biovectra, Revolution Biomanufacturing Partner to Streamline mRNA Development & Scale-Up

Collaboration combines sequence design expertise with end-to-end GMP manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Biovectra, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. have announced a collaboration that grants Biovectra access to Revolution Biomanufacturing’s proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.

This partnership provides a fully integrated pathway from mRNA sequence design through sterile drug product manufacturing, supporting customers with end-to-end development and production capabilities.

Through this alliance, sponsors gain access to a seamless workflow that begins with mRNA sequence design to improve expression and stability, followed by process development, scale-up, technology transfer, and GMP production of plasmid DNA (pDNA), mRNA, lipid nanoparticles (LNP), and sterile drug product for clinical use.

“We are thrilled to partner with Biovectra, whose deep experience in GMP manufacturing and commitment to scientific excellence make them an ideal collaborator,” said Molly McGlaughlin, CEO of Revolution Biomanufacturing. “By integrating Revolution Biomanufacturing’s advanced sequence optimization technologies with Biovectra’s end-to-end GMP manufacturing, we’re creating a clearer, more reliable path from design to drug product for our customers – one that reduces risks tied to supply disruptions, miscommunication, and failed process transfers.”

“This collaboration strengthens our ability to support innovators developing the next generation of mRNA therapeutics,” said Normand Blais, AVP, Product Development of Biovectra. “In pairing Revolution Biomanufacturing’s sequence engineering with Biovectra’s integrated development and manufacturing solutions, we’re helping developers enhance protein expression, determine sequence faster, and move to the clinic with confidence.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics